Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRAS | P01112 | 13/20 | 0.51 |
| ▸ | ESR1 | P03372 | 13/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 13/20 | 0.51 |
| ▸ | TOP1 | P11387 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5889526 | 0.97 | HRAS (0.53) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL6489771 | 0.91 | HRAS (0.47) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL6486747 | 0.90 | HRAS (0.46) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL5889501 | 0.88 | HRAS (0.51) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL5889546 | 0.88 | HRAS (0.42) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL5889554 | 0.87 | HRAS (0.52) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL5889659 | 0.86 | HRAS (0.41) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL5889825 | 0.86 | HRAS (0.43) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL6503130 | 0.85 | TOP1 (0.53) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL5889536 | 0.84 | TERT (0.42) | SMN1; SMN2NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6849713-B2 | Compounds possessing antibacterial, antifungal or antitumor activity | GENELABS TECHNOLOGIES, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20020037856-A1 | Novel compounds possessing antibacterial, antifungal or antitumor activity | GENELABS TECHNOLOGIES, INC. | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037856-A1 | Novel compounds possessing antibacterial, antifungal or antitumor activity | CYP51A1, MCL1, ERG28 | HRAS 402/4885ESR1 4097/4885ESR2 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.